12 November 2024 — AstraZeneca and Daiichi Sankyo have submitted a new Biologics License...
Author - David Miller
Abeona Therapeutics Announces FDA Acceptance of BLA Resubmission...
CLEVELAND, Nov. 12, 2024 (GLOBE NEWSWIRE) — Abeona Therapeutics Inc. (Nasdaq: ABEO) today...
Acalabrutinib-Venetoclax Prolongs Survival in Previously...
FRIDAY, Feb. 21, 2025 -- For patients with previously untreated chronic lymphocytic leukemia (CLL)...
Epidural Steroid Injections Reviewed for Radicular Pain, Spinal...
FRIDAY, Feb. 21, 2025 -- There is some evidence for epidural steroid injections (ESIs) reducing...
Soleno Therapeutics Announces FDA Extension of Review Period for...
REDWOOD CITY, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) — Soleno Therapeutics, Inc...
Arrowhead Pharmaceuticals Submits New Drug Application to U.S...
PASADENA, Calif.–(BUSINESS WIRE)–Nov. 18, 2024– Arrowhead Pharmaceuticals, Inc. (NASDAQ:...
Black Patients With Cancer Still Have Higher Mortality Rates...
FRIDAY, Feb. 21, 2025 -- Cancer mortality has decreased among Black Americans, but they still have...
Satsuma Pharmaceuticals and SNBL Receive FDA Acceptance of NDA...
DURHAM, N.C., Nov. 26, 2024 /PRNewswire/ — Satsuma Pharmaceuticals, Inc., a late-stage...
Applied Therapeutics Receives Complete Response Letter from U.S...
NEW YORK, Nov. 27, 2024 (GLOBE NEWSWIRE) — Applied Therapeutics, Inc. (Nasdaq: APLT), a...
Olpasiran Leads to Significant Reduction in Oxidized...
FRIDAY, Feb. 21, 2025 -- Olpasiran, a small interfering RNA, which blocks lipoprotein(a) (Lp[a])...